Symbols

LSB(Delisted)

LakeShore Biopharma·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About LSB

Lakeshore Biopharma Co., Ltd

A global biopharmaceutical company developing next-generation vaccines and therapeutics

Industry

Established Date

Listing Date

08/05/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

573

Fiscal Year Ends

03-31

Website

www.lakeshorebio.com

Security Type

Common stock

Office address

Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, PRC 102629

Business

Introduction

Lakeshore Biopharmaceuticals Limited was established in November 2020 under the laws of the Cayman Islands. Lakeshore Bio, a Nasdaq listed company in the United States, is a comprehensive biopharmaceutical company integrating the production, sales and research and development of vaccine biological products, focusing on the research and development and production of vaccines and other immune products in the field of infectious diseases. At this stage, the main product sold by the company is freeze-dried human rabies vaccine (Vero cells); the cumulative sales of this product since its launch have exceeded 100 million. With its unique PIKA immune regulation technology, the company has been listed as a "National Major New Drug Creation Project" three times. The company's core product, Yisheng Junan Vaccine, is the first aluminum-free adjuvant rabies vaccine in China. It has a safe use record of hundreds of millions of people and has a domestic market share of up to 40%. The therapeutic PIKA rabies vaccine (VERO cells) developed by the company is a "major new drug creation project" of the Ministry of Science and Technology; the company's existing products under development also include: PIKA rabies vaccine (human diploid), PIKA Covid-19 vaccine, PIKA hepatitis B vaccine, etc. The company is located in the Biomedical Industrial Park of Fengtai District, Beijing and Shenbei New District, Shenyang City, Liaoning Province. There are more than 1,000 R&D personnel and various employees. The core R&D personnel of the company have an average of more than 15 years of experience in vaccine development and commercialization, which has deep development potential and a good foundation for development. Internationally renowned investment institutions such as Haisong Capital, Hillhouse Capital, Fidelity Fund, Cambridge Capital, and Bill Gates Foundation are all important investors of the company, and have invested more than US $400 million in the company. Lakeshore Bio has always adhered to the mission of "escorting human health" and strictly controlled the quality of vaccines. At the same time, it adheres to the core values of "rigorous and pragmatic, excellence, pursuit of excellence, and win-win cooperation" to escort the company's development and make greater contributions to human health.

Company Financials

EPS

LSB has released its 2024 Q2 earnings. EPS was reported at -0.16, versus the expected -0.1, missing expectations. The chart below visualizes how LSB has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

LSB has released its 2024 Q4 earnings report, with revenue of 18.75M, reflecting a YoY change of 21.43%, and net profit of -25.09M, showing a YoY change of -112.04%. The Sankey diagram below clearly presents LSB's revenue sources and cost distribution.